Abstracts Archive - Page 1652 of 2607 - ACR Meeting Abstracts

Abstract Number: 788 • 2016 ACR/ARHP Annual Meeting
Unresolving C4 Hypocomplementemia Associates with a Different Spectrum of Disease in SLE and Is More Important Than Transiently Low Levels
Laura Durcan¹, Wei Fu² and Michelle Petri³, ¹University of Washington, Seattle, WA, ²Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ³Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Hypocomplementemia is common in systemic lupus erythematosus (SLE) and is included in classification criteria and disease activity indices. Whether persistently low complement levels (C3,…
Abstract Number: 789 • 2016 ACR/ARHP Annual Meeting
Use of Nominal Group Technique to Determine Candidate Items for SLE Classification Criteria Development
Sindhu R. Johnson¹, Dinesh Khanna², Ricard Cervera³, Nathalie Costedoat-Chalumeau⁴, Dafna D. Gladman⁵, Bevra H. Hahn⁶, Falk Hiepe⁷, Jorge Sanchez-Guerrero⁸, Elena Massarotti⁹, Dimitrios Boumpas¹⁰, Karen H. Costenbader¹¹, David I. Daikh¹², David Jayne¹³, Thomas Dörner¹⁴, Diane L. Kamen¹⁵, Marta Mosca¹⁶, Rosalind Ramsey-Goldman¹⁷, Josef S. Smolen¹⁸, David Wofsy¹⁹ and Martin Aringer²⁰, ¹Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²University of Michigan, Ann Arbor, MI, ³Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, ⁴Internal Medicine, Cochin University Hospital, Paris, France, ⁵Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁶Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁷Charité – Universitätsmedizin, Berlin, Germany, ⁸University of Toronto, Toronto, Canada; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁹Rheumatology, Immunology, & Allergy, Harvard Medical School, Brigham & Women's Hosp, Boston, MA, ¹⁰University of Athens, Athens, Greece, ¹¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹²Rheumatology, UCSF/VA Medical Center, San Francisco, CA, ¹³Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom, ¹⁴Department of Medicine/Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ¹⁵Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ¹⁶Clinical and Experimental Medicine, University of Pisa, Rheumatology Unit, Pisa, Italy, ¹⁷FSM, Northwestern University, Chicago, IL, ¹⁸Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ¹⁹University of California, San Francisco, San Francisco, CA, ²⁰Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany
Background/Purpose: Criteria for the classification of SLE are being developed with the support of EULAR and ACR. Two independent exercises (expert-based Delphi exercise and data-driven…
Abstract Number: 790 • 2016 ACR/ARHP Annual Meeting
Assessment of the Construct Validity of the Lupus Low Disease Activity State (LLDAS) – an Expert Opinion Case Study
Vera Golder¹, Molla Huq², Kate Franklyn³, Alicia Calderone⁴, Aisha Lateef⁵, Chak Sing Lau⁶, Sandra V. Navarra⁷, Timothy Godfrey^4,8, Shereen Oon⁴, Alberta Y. Hoi³, Eric F Morand³, Mandana Nikpour⁹ and Asia Pacific Lupus Collaboration, ¹Southern Clinical School, Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ²Department of Medicine (Rheumatology), Melbourne University, Melbourne, Australia, ³Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ⁴St. Vincent’s Hospital, Melbourne, Australia, ⁵Medicine/Rheumatology, National University Health System, Singapore, Singapore, ⁶Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ⁷Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ⁸63 Sutton Street, St. Vincent’s Hospital, Melbourne, Australia, ⁹Melbourne University, Melbourne, Australia
Background/Purpose: Systemic lupus erythematosus (SLE) has historically lacked clear treat-to-target definitions. The recently reported Lupus Low Disease Activity State (LLDAS) definition, combining disease activity and…
Abstract Number: 791 • 2016 ACR/ARHP Annual Meeting
The International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP) Initiative – Update and Its Impact
Edward K.L. Chan¹, Jan Damoiseaux², Gabriel Carballo³, Karsten Conrad⁴, Wilson de Melo Cruvinel⁵, Paulo Francescantonio⁵, Marvin J. Fritzler⁶, Ignacio Garcia-De La Torre⁷, Manfred Herold⁸, Tsuneyo Mimori⁹, Minoru Satoh¹⁰, Carlos Von Muhlen¹¹, Luis E C Andrade¹² and representing committee and translation team members, ¹Dept of Oral Biology, University of Florida, Gainesville, FL, ²Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, Netherlands, ³Hospital Carlos G. Durand, Buenos Aires, Argentina, ⁴Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ⁵Pontifícia Universidade Católica de Goiás, Goiânia, Brazil, ⁶Medicine, University of Calgary, Calgary, AB, Canada, ⁷Immunology & Rheumatology, Centro de Est. de Invest. Bas. y Clin., S.C., Guadalajara, JAL, Mexico, ⁸Medical University of Innsbruck, Innsbruck, Austria, ⁹Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁰Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹¹Rheumatology, Rheuma Clinic Dr. von Muhlen, Porto Alegre, Brazil, ¹²Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: The indirect immunofluorescence (IIF) pattern observed in the antinuclear antibody (ANA) test provides an initial assessment of autoantibody responses in candidate patients who have…
Abstract Number: 792 • 2016 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] Response Is Associated with Global Benefit in Patients with Moderate to Severe SLE
R Furie¹, L Wang², J Drappa² and G Illei², ¹Northwell Health, Great Neck, NY, ²MedImmune, Gaithersburg, MD
Background/Purpose: Post-hoc analysis of two Phase III studies of belimumab1 showed that an SRI(4) response is associated with clinically meaningful benefits, irrespective of treatment assignment.…
Abstract Number: 793 • 2016 ACR/ARHP Annual Meeting
Multi-Parametric Model Development for Assessing Lupus Nephritis and Disease Activity
Christopher Sjöwall¹, Chelsea Bentow², Mary Ann Aure², Gabriella Lakos², Peter Martis² and Michael Mahler², ¹Rheumatology/AIR, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ²Research and Development, Inova Diagnostics, San Diego, CA
Multi-parametric model development for assessing lupus nephritis and disease activity Christopher Sjӧwall1, Chelsea Bentow2, Mary Ann Aure2, Gabriella Lakos2, Peter Martis2, Michael Mahler2 1AIR/Rheumatology, Department…
Abstract Number: 794 • 2016 ACR/ARHP Annual Meeting
Development and Initial Validation of a Novel Lupus Disease Activity Index to Account for Glucocorticoids: Sledai-2K Glucocorticoids Index (SGI)
Zahi Touma¹, Dafna D Gladman², Jiandong Su³ and Murray Urowitz¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: It is challenging to describe disease activity in SLE in the context of multiple levels of glucocorticoids (GC) treatment. We aim to develop and…
Abstract Number: 795 • 2016 ACR/ARHP Annual Meeting
Low Disease Activity in Systemic Lupus Erythematosus: An Achievable Goal?
Chiara Tani¹, Roberta Vagelli¹, Chiara Stagnaro², Linda Carli^3,4, Viola Signorini⁵ and Marta Mosca¹, ¹Clinical and Experimental Medicine, University of Pisa, Rheumatology Unit, Pisa, Italy, ²Department of Clinical and Experimental Medicine, University of Pisa, Rheumatology Unit, Pisa, Italy, ³GenOMec PhD, University of Siena, Italy, ⁴Clinical and Experimental Medicine, Rheumatology Unit, Pisa, Italy, ⁵Rheumatology Unit, Pisa, Italy
Background/Purpose: To date, there is no generally accepted definition for remission in SLE, thus a possible goal in the treat-to-target strategy might be low disease…
Abstract Number: 796 • 2016 ACR/ARHP Annual Meeting
Establishment of an International Autoantibody Standard for Anti-DFS70/LEDGF Antibodies: Proof-of-Concept Study for a Novel Strategy for the Setting up of International Autoantibody Standards
Alessandra Dellavance¹, Danielle Baldo¹ and Luis Eduardo C. Andrade², ¹Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil, ²Rheumatology, Escola Paulista de Medicina, Universidade Federal de São Paulo, UNIFESP-EPM, Sao Paulo, Brazil
Background/Purpose: Robust, certified, and traceable reference material for autoantibody testing is vital for the validity of results obtained in the clinical laboratory. International standards for…
Abstract Number: 797 • 2016 ACR/ARHP Annual Meeting
Randomized Clinical Trials of Systemic Lupus Erythematosus: Evaluating Differences in the Enrolled Populations
Niti Goel^1,2, Brandon Barrett³, Ann Duncan⁴, Margaret-Beth Gallagher¹ and Marsha Mackey³, ¹Quintiles, Inc., Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Quintiles, Inc., Rockville, MD, ⁴Quintiles, Inc., Reading, Berkshire, United Kingdom
Background/Purpose: Background/Purpose: Randomized controlled trials (RCTs) in SLE identify specific populations of interest for eligibility, but still vary in the recruited populations. These differences may…
Abstract Number: 798 • 2016 ACR/ARHP Annual Meeting
Oxidized Phospholipids,Lipoprotein(a) and Glycosphingolipid Associated B-1,4 Galactosyltransferase in a Johns Hopkins Cohort of Patients with Systemic Lupus Erythematosus
Subroto Chatterjee¹, Michelle Petri², Steven Jones³ and Vignesh Sadras¹, ¹Pediatrics-Cardiology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Oxidized Phospholipids, Lipoprotein (a) and Glycosphingolipid Associated B- 1,4 Galactosyltransferase in a Johns Hopkins cohort of patients with Systemic Lupus Erythematosus. Background/Purpose: Systemic lupus erythematosus(SLE)…
Abstract Number: 799 • 2016 ACR/ARHP Annual Meeting
Biomarker Identification & Molecular Sub-Classification in Systemic Sclerosis for Precision Medicine Using RNA-Seq
Elisha D.O. Roberson^1,2, Li Cao¹, David J. Morales-Heil¹, Benjamin Korman³ and John Varga⁴, ¹Department of Medicine, Washington University, St. Louis, MO, ²Department of Genetics, Washington University, St. Louis, MO, ³Department of Rheumatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁴Rheumatology and Dermatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL
Background/Purpose: Systemic sclerosis (SSc) is a complex and highly heterogeneous disease with multi-organ involvement. Accurate tools for disease sub-classification are lacking. In most patients, skin…
Abstract Number: 800 • 2016 ACR/ARHP Annual Meeting
An Altered Cardiovascular System Development Gene Expression Signature in Skin is a Hallmark of Limited Cutaneous Systemic Sclerosis
Emma C. Derrett-Smith^1,2, Viktor Martyanov³, Cecilia B. Chighizola⁴, Pia Moinzadeh⁵, Korsa Khan⁶, Tammara A. Wood³, Pier Luigi Meroni⁷, David Abraham⁸, Voon H. Ong⁹, Michael Whitfield³ and Christopher Denton⁸, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London, United Kingdom, ²Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Department of Clinical Sciences and Community Health, University of Milan, IRCCS Istituto Auxologico Italiano, Milano, Italy, ⁵Department of Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁶Centre For Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London, United Kingdom, ⁷Rheumatology Department, University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁸Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁹Rheumatology, UCL Division of Medicine, London, United Kingdom
Background/Purpose: Limited cutaneous SSc (lcSSc) is characterised by less extensive skin fibrosis but patients can develop major internal organ complications and vascular manifestations. Gene expression…
Abstract Number: 801 • 2016 ACR/ARHP Annual Meeting
Multi-Tissue Gene Expression Pathway Analysis of Emerging Therapeutics in a TGFβ Dependent Mouse Model of Systemic Sclerosis
Emma C. Derrett-Smith^1,2, Shiwen Xu³, Rachel K. Hoyles⁴ and Christopher Denton⁵, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London, United Kingdom, ²Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Division of Medicine, Centre for Rheumatology and Connective tissue disease, University College London, London, United Kingdom, ⁴Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, ⁵Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom
Background/Purpose: We have previously investigated the interplay between TGFβ, BMP, VEGF and endothelin in SSc using the TβRIIΔk-fib strain, a transgenic mouse model in…
Abstract Number: 802 • 2016 ACR/ARHP Annual Meeting
Whole Transcriptome Profiling through RNA Sequencing Reveals Differentially Expressed Sense-Antisense Gene Pairs in Patients with Systemic Sclerosis
Tobias Messemaker^1,2, Loubna Chadli³, Varshna Goelela³, Maaike Boonstra⁴, Annemarie Dorjee⁴, Stefan Andersen³, Harald Mikkers², Tom WJ Huizinga⁴, Zhenghui Li⁵, Guoshuai Cai⁵, Michael Whitfield⁶, René Toes⁷, Jamil Aarbiou³, Jeroen De Groot³, Jeska K. de Vries-Bouwstra⁴ and Fina Kurreeman⁴, ¹Department of Rheumagoloty, Leiden University Medical Center, Leiden, Netherlands, ²Department of Molecular cell Biology, Leiden University Medical Center, Leiden, Netherlands, ³Charles River Nederland B.V., Leiden, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁶Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of skin and multiple organs. Morbidity and mortality are high and pathogenesis is poorly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].